Podcasts about Capella Space

The $318 million IonQ purchase deal to acquire Capella Space is bringing together two worlds in a high-stakes bid to radically change satellite-to-satellite and satellite-to-ground communications and computing at the edge. At least that's what the CEOs are saying. Are they right? Also, up top in this episode is a space threats update. Laura Winter speaks with Niccolo de Masi, IonQ's President and CEO; Frank Backes, CEO of Capella Space; and Hector Falcon, the Space Information Sharing and Analysis Center's Watch Center Director.

Could vast chambers beneath Giza's pyramids hide ancient consciousness technology? What if the Hall of Records, Amenti, and the Duat exist as physical gateways to other dimensions or repositories of Zep Tepi knowledge? The boundary between archaeological fantasy and undiscovered reality remains blurred, leaving humanity's most profound secrets potentially waiting in darkness beneath the sands.​​If you are having a mental health crisis and need immediate help please go to ​https://troubledminds.org/help/ and call somebody right now. Reaching out for support is a sign of strength.​​LIVE ON Digital Radio! Http://bit.ly/40KBtlW​​http://www.troubledminds.net or ​https://www.troubledminds.org​​Support The Show!​https://www.spreaker.com/podcast/troubled-minds-radio--4953916/support​https://ko-fi.com/troubledminds​https://patreon.com/troubledminds​https://www.buymeacoffee.com/troubledminds​https://troubledfans.com​​Friends of Troubled Minds! - ​https://troubledminds.org/friends​​Show Schedule Sun--Tues--Thurs--Fri 7-10pst​iTunes - ​https://apple.co/2zZ4hx6​Spotify - ​https://spoti.fi/2UgyzqM​TuneIn - ​https://bit.ly/2FZOErS​Twitter - ​https://bit.ly/2CYB71U​----------------------------------------​​https://troubledminds.substack.com/p/the-secret-in-the-sands-finding-the​​https://www.ancient-origins.net/ancient-places-africa/36400-bc-historical-time-zep-tepi-theory-002617​​https://x.com/derek__olson/status/1902858330806292950​​https://www.ancient-code.com/the-zep-tepi-the-creation-of-ancient-egypt/​​https://www.ancientpages.com/2021/05/23/zep-tepi-when-gods-established-their-kingdom-on-earth-in-egypt/​​https://www.capellaspace.com/​​https://en.wikipedia.org/wiki/Capella_Space​​https://x.com/goodmorningufo/status/1902808803445444955​​https://www.newsweek.com/archaeologists-discover-mysterious-underground-anomaly-near-giza-pyramids-1900087​​https://yournews.com/2025/03/20/3316118/sar-imaging-reveals-massive-subsurface-structures-beneath-khafre-pyramid/​​https://symbolsage.com/duat-egyptian-realm-dead/​​https://www.ancient-origins.net/ancient-places-africa/three-famous-sites-one-story-legendary-city-tanis-006933​​https://www.nationalgeographic.com/history/article/tanis-egypt​​https://www.bbc.com/news/articles/cgr2n8xx5gyo​​https://egyptmythology.com/the-duat-a-journey-into-the-egyptian-underworld/​​https://www.biblicalcyclopedia.com/A/amenti.html

Here's a podcast description for our GEOINT 2024 recap episode, highlighting major themes from the conference. This is an AI podcast experiment aggregating our content helping analyze and bring focus on what's important. Tune in and listen in. Join us for a deep dive into the highlights of the GEOINT 2024 Symposium! This year's conference in Orlando, Florida, was packed with exciting developments, and we're here to break down the key themes and trends that emerged. We'll explore how the geospatial intelligence community is evolving, discussing everything from cutting-edge technologies to the expanding role of commercial partnerships. In this episode, we'll cover: * The Proliferation of Satellites and Data: The sheer number of satellites being launched, including small sats with impressive capabilities, is revolutionizing GEOINT. We'll discuss the implications of this increased access to imagery, the variety of sensors, and how it impacts different markets. * The Rise of AI and Machine Learning: Artificial intelligence (AI) and machine learning (ML) are no longer just buzzwords. They're critical for analyzing the vast amounts of data being generated. We'll explore how these technologies are being used in areas such as cloud removal from imagery, object detection, and identifying lithium mines. We'll also examine how the industry is tackling the challenge of labeling data to build reliable AI tools. * The Importance of Open Data and Standards: The need for open data and interoperability was a major topic of conversation. We will discuss the importance of machine-readable data, ethical considerations, and the efforts of organizations like the Open Geospatial Consortium (OGC) in setting standards. * Commercial Partnerships and Innovation: The increasing role of commercial companies and their innovative solutions was clear. We'll touch on how these partnerships are driving progress and what it means for the future of the industry. This includes discussions of commercial providers like Albedo, Astera, Capella Space, Maxar, and Pixxel. * Cybersecurity and Data Protection: With the increase in data and reliance on technology, security is paramount. We'll discuss the need to safeguard data, address potential cyber threats, and explore strategies for managing risk in a complex environment. * Workforce Development and Data Literacy: There's a growing need to train analysts and other professionals to effectively use the available data and tools. We'll touch on initiatives to increase data literacy, as well as the critical role of coaching to optimize personnel. * The Expansion of GEOINT Applications: GEOINT is expanding beyond its traditional defense and intelligence applications into a variety of sectors including agriculture, energy, disaster response, and financial services. We'll look at some of these non-traditional areas where geospatial data is making an impact.

音频文字发布在公众号“北京读天下”，《价值创造与商业模式》在公众号微店有优惠。每周新书听友群微信号：yinmingshu002。2024年全球商业遥感排名，在X波段SAR卫星部分，前三名是Umbra，Capella和冰眼，在重访时间方面，前三名是冰眼、Umbra和Capella。[i]在总共11项的总排名中，中国第一，美国第二。Capella，Umbra和冰眼三家企业都属于小型SAR卫星运营，它们在竞争战略上的区别主要在于垂直整合的程度。Capella选择了最完整的垂直整合，卫星—数据—分析—用户，用SaaS和API优先的模式向终端用户提供直观的结果。Umbra放弃了垂直整合，专注卫星和数据，将分析业务交给专业机构。Umbra的选择是技术优先，注重图像分辨率， Capella是用户体验优先，通过用户应用来拉动市场。冰眼的战略在两者之间，在用户端，冰眼采用定制化咨询服务。[i] https://syntheticapertureradar.com/umbra-usa-winning-but-china-is-close-behind-in-sar-gold-rush/

Capella Space是一家航天创业企业，它的主要业务是SAR卫星设计制造、轨道卫星管理和地表观测图像处理。Capella是新兴的空间经济产业代表，它的创建与空间技术成熟和市场需求有关，也得益于行业管制的开放。在Capella的创业故事中，美国国防部的秘密使命和创业者个人动机都扮演着重要角色。

SpaceX's Polaris Dawn mission is scheduled to launch on August 26. Dawn Aerospace have completed another flight test campaign of the Mk-II rocket-powered aircraft. Rocket Lab has scheduled a 14-day launch window that opens on August 11th for its 52nd Electron mission which will deploy a satellite for Capella Space, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our weekly intelligence roundup, Signals and Space, and you'll never miss a beat. And be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Kelly Haston, PhD, Commander of the last Crew Health and Performance Exploration Analog (CHAPEA) mission which ended on July 6, 2024.  You can connect with Kelly on LinkedIn and learn more about CHAPEA on NASA's website. Selected Reading https://x.com/PolarisProgram/status/1821260140210745531 Campaign 2-2 Update, and Our Journey Through Flight Test — Dawn Aerospace Rocket Lab Schedules Next Electron Launch Just Eight Days After Previous Mission- Business Wire Quarterly Results- Viasat, Inc. Redwire Corporation Reports Second Quarter 2024 Financial Results- Business Wire MDA Space Reports Second Quarter 2024 Results BlackSky Reports Second Quarter 2024 Results- Business Wire Virgin Galactic Announces Second Quarter 2024 Financial Results And Provides Business Update Air Force Research Lab eyes space data transport demo in 2026 PLD Space to start building French Guiana launch facilities next month - SpaceNews 10 Smallsat Startups to Watch in 2024- Via Satellite Find Out What God Needs With A Starship When William Shatner Hosts A Live 35th Anniversary Screening of "Star Trek V: The Final Frontier" at GalaxyCon San José with First-Ever Live Commentary T-Minus Crew Survey We want to hear from you! Please complete our 4 question survey. It'll help us get better and deliver you the most mission-critical space intel every day. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

The National Security Space Association's independent think tank, The Moorman Center for Space Studies, has released a report called "America's Asymmetric Vulnerability to Navigation Warfare: Leadership and Strategic Direction Needed to Mitigate Significant Threats."  Intuitive Machines has finalized the IM-2 mission landing region ahead of its sold-out second mission.  Rocket Lab's next Electron launch will move to a later date at the request of mission partner Capella Space, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our weekly intelligence roundup, Signals and Space, and you'll never miss a beat. And be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Yanni Barghouty, CEO and Cofounder of Cosmic Shield Corporation.  You can connect with Yanni on LinkedIn and learn more about Cosmic Shield on their website. Selected Reading The Moorman Center for Space Studies, the National Security Space Association's independent think tank, releases a report entitled, "America's Asymmetric Vulnerability to Navigation Warfare: Leadership and Strategic Direction Needed to Mitigate Significant Threats" authored by Marc Berkowitz Intuitive Machines Finalizes Landing Site for Sold-out IM-2 Lunar Prospecting Mission Polaris Dawn crew completes final series of EVA spacesuit testing Rocket Lab Launch Update- Business Wire Momentus Announces Convertible Note, Loans, and Successful Completion of Annual Meeting- Business Wire L3Harris Announces Quarterly Dividend- Business Wire Space Firms Seek to Recruit SpaceX Workers Hurt by Musk's Plan to Move to Texas - Bloomberg NASA, Boeing Complete Starliner Engine Testing, Continue Analysis NASA Space ROS Sim Summer Sprint Challenge US Space Force Prepares Jammers to Blunt Russia, China Satellites - Bloomberg Space Force OKs 'trial' software to vet commercial, foreign space monitoring data - Breaking Defense https://www.spaceappschallenge.org/nasa-space-apps-2024/ T-Minus Crew Survey We want to hear from you! Please complete our 4 question survey. It'll help us get better and deliver you the most mission-critical space intel every day. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

Capella Space is a company that specializes in synthetic aperture radar (SAR) satellites. They have a vertically integrated capability with high-resolution imaging and strong signal transmission. They currently have four satellites in orbit and plan to launch more. Capella has faced supply chain challenges but has adapted by signing contracts with multiple companies. They have also established successful partnerships with analytics companies to make SAR data more consumable. SAR has traditionally been used in the military and intelligence industry but is now seeing growth in non-military applications. One of the biggest hurdles for the industry is turning SAR data into human-readable and machine-readable information. Capella recently launched a satellite with fully automated deployment capability, which enhances their resiliency and ability to reconstitute satellite capability in case of a catastrophic event.

Space Competition: Why SpaceX's “Rapid Unscheduled Disassembly” Is Redrawing The Map To Success This week's episode is coming from the annual Satellite in Washington, D.C. Instead of having a panel, Laura Winter is in the exhibition hall to ask commercial space leaders about risk, success and failure in the Age of SpaceX. Winter speaks with Frank Backes, CEO of Capella Space; Martin Cullen, TE Connectivity's Senior Manager for Business Development and Strategy; Kayhan Space Co-Founders Siamak Hesar and Araz Feyzi; Matthew Randall, Empulsion Inc.'s Director of Business Development; and Namrata Goswami, an independent scholar on space policy and great power politics and co-author of the book “Scramble for the Skies”.

Space Money: When Nation States Target The Commercial Space Sector This month, two years ago, Russia's unprovoked invasion of Ukraine started with a cyber attack that changed everything and yet nothing for the U.S. commercial space sector. This is the first in a series of episodes examining cyber attacks and space systems. Laura Winter speaks with Nick Saunders, Viasat's Chief Cybersecurity and Data Officer for Government Systems, in his first sit-down interview since the satellite communications company weathered a notorious cyberattack on February 24, 2022; Erin Miller, the Space Information Sharing and analysis Center's Executive Director; and Frank Backes, CEO of Capella Space, a company providing earth observation products to government commercial customers.

Iran claims it sent animals to space. DARPA picks its 14 faves to study what's possible in lunar services. SpaceX adds a key demo for NASA to its next Starship flight test plan. And we have the latest updates from the Earth Observation Market, and a look at the year that was, with our guest Aravind Ravichandran in our monthly Overview segment. And more! Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our weekly intelligence roundup, Signals and Space, and you'll never miss a beat. And be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest We have the latest updates from the Earth Observation Market with our guest Aravind Ravichandran. Selected Reading Iran launches animals into space as it revives bid for human missions- Al Jazeera Collaborating Toward Integrated Commercial Lunar Infrastructure- DARPA Exolaunch USA Wins Launch Contract from Capella Space for Pioneering SAR Satellite Mission- ExoLaunch  SpaceX plans key NASA demonstration for next Starship launch- CNBC Rogue Space Systems Announces Barry-1 Satellite Launch and Operations Commencement- Rogue Space Aalyria Wins Contract with European Space Agency to Build O-RAN Compliant Orchestration Platform to Unlock 5G/6G Non-terrestrial Connectivity- Business Wire Japan targeting Jan. 19 for nation's 1st-ever moon landing- Space  UAE Organizes First Space Agencies' Leaders Summit during COP28- SpaceWatch NASA Leaders to Highlight 25th Anniversary of Space Station with Crew- NASA Maine manufacturer of high-temp materials will expand, driven by defense, space industries- Mainebiz.biz Start of new space race? First private spacecraft may land on the Moon as early as next month- Times of India T-Minus Crew Survey We want to hear from you! Please complete our 4 question survey. It'll help us get better and deliver you the most mission-critical space intel every day. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © 2023 N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

A Rocket lab Electron rocket has failed soon after take-off in Māhia. Rocket Lab has apologised after an "issue" occurred two-and-a-half minutes into flight at 7 o'clock Tuesday night, after it had completed a first stage burn and stage separation as planned. It's 41st mission, the launch was for one of its partners, Capella Space, an American provider of commercial radar imagery. University of Auckland professor of physics Richard Easther spoke to Corin Dann.

Rocket Lab successfully lifts Capella Space satellites to orbit and marks its 40th Electron launch. North Korea's second attempt to launch a spy satellite ends in failure. Australian startup HEO raises $8 million in Series A funding to develop its space imagery platform, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our weekly intelligence roundup, Signals and Space, and you'll never miss a beat. And be sure to follow T-Minus on Twitter and LinkedIn. T-Minus Guest Our guests today are Giulia Salmaso and Salvatore Grignano from the Italian Trade Agency on their new accelerator program “Space It Up”.  You can connect with Guilia, Salvatore and ITA on LinkedIn and learn more about Space It Up at Space.N2k.com/ITA. Selected Reading Rocket Lab Launches 40th Electron Mission, Successfully Flies Reused Engine- Business Wire North Korea's space launch program and long-range missile projects- Reuters Chandrayaan-3 on Moon: India to shift focus on Chandrayaan-4 with Japan- India Today Blue Blocks School Celebrates Successful Inauguration of Innovative Space Lab SES Signs Broadband Deal in the Philippines With We Are IT- Via Satellite Airtree leads $12m Series A for space imagery enabler HEO Robotics- Business News Australia Momentus to Provide Hosted Payload Services for FOSSA Systems- Business Wire SAB Orbital Vehicle Could Work in Concert With Space Rider - European Spaceflight  Space Foundation Partners With The Netherlands Ministry Of Foreign Affairs To Support And Promote Dutch Space Sector In U.S.‘ He's made a huge sacrifice': US astronauts praise Frank Rubio for staying a year in space  A Lexicon for Outer Space Security- UNIDIR European astronomers detect new component of radio halo in a nearby galaxy cluster  NASA Begins Integrating ‘Nervous System' for Roman Space Telescope- NASA T-Minus Crew Survey We want to hear from you! Please complete our 4 question survey. It'll help us get better and deliver you the most mission-critical space intel every day. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © 2023 N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

SpaceX to launch from both US coasts in one day. US Space Force GPS ground system overhaul delayed. US House Republicans have proposed a bill to make the National Oceanic and Atmospheric Administration an independent agency. Capella Space has been awarded a 5-year blanket purchase agreement with NASA‘s Earth Science Division, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our weekly intelligence roundup, Signals and Space, and you'll never miss a beat. And be sure to follow T-Minus on Twitter and LinkedIn. T-Minus Guest Our guest for today's episode is Aaron Myrick, Project Leader at The Aerospace Corporation. Aaron worked on the Moonlighter - the satellite hacking sandbox, now on orbit. You can connect with Aaron on LinkedIn and follow the Aerospace Corporation on their website. Selected Reading SpaceX knocks out overnight Space Coast launch; California launch on tap- Orlando Sentinel NASA astronauts deploy 5th roll-out solar array on spacewalk outside space station- Space.com Space Force sees further delays to ‘troubled' GPS ground segment- C4ISRNET House Republicans introduce bill to create an independent NOAA- SpaceNews BAE Systems announces low earth orbit cluster for secure digital military intelligence- AeroMag HawkEye 360's Cluster 7 Satellites Are Now Operational- Via Satellite Capella Space Wins Five-Year SAR Imagery Purchase Deal from NASA US-German Satellites Show California Water Gains After Record Winter- NASA Layoffs hit Colorado space companies as funding remains tight- CNBC Coast Guard in coordination with Chinese Embassy over suspected rocket debris- PhilStar Audience Survey We want to hear from you! Please complete our 4 question survey. It'll help us get better and deliver you the most mission-critical space intel every day. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © 2023 N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

On The Space Show for Wednesday, 15 March 2023: Space Show News: Rocket Lab, a global leader in launch services and space systems, announced it has established a new wholly-owned subsidiary, Rocket Lab Australia, to explore opportunities to support the expansion of Australia's national space capabilities. Rocket Lab to launch multiple Acadia Earth-imaging satellites for Capella Space, an American space tech company and a leading provider of commercial Synthetic Aperture Radar (SAR) imagery. Spaceflight Inc. Readies BlackSky Satellites for Upcoming Rocket Lab Launch. NASA to reveal the Artemis Moon mission spacesuit designed by Axiom Space NASA announces the selection of Axiom Space to provide the third private mission to the International Space Station Detection of barium in the atmospheres of WASP-76b and WASP-121b exoplanets. What's with Dark Matter?: DAMPE and VLAST hope to find out. Skykraft satellites are operational in orbit but how many of them are there? Planet Earth: Season 4 - Episode 46 Pamela Melroy and the Earth System Observatory satellites and the Earth Information Centre China launches a pair of geographic mapping, land resource surveys and science experiments NASA's Compact Total Irradiance Monitor (CTIM) cubesat Tianhe 6A and 6b; CTIM 1; ICEYE; GeoCarb; GRACE-FO; Landslide Hazards; SWOT. (Inserts courtesy NASA HQ, ICEYE, USRA & JPL).

Planet was founded in 2010 as Cosmogia by former NASA scientists Will Marshall, Robbie Schingler and Dr. Christopher Boshuizen. The three scientists-turned-entrepreneurs had a singular vision: to image the entire Earth every day to make changes visible, accessible and actionable. They were the first to deploy cubesats in a commercial capacity, and over the past decade, they succeeded in revolutionizing the Earth observation (EO) industry and expanding access to satellite-based data far beyond the traditional defense, intelligence and agricultural sectors. The co-founders planned to design and build their own cubesats called Doves for launch into low Earth orbit. Their first satellite was built in the archetypal California garage. Successful fundraising permitted them to launch two demonstration satellites, Dove 1 and 2, in April 2013 and two more in November, by which time the company had announced plans for a 28-satellite constellation called Flock-1. The flock was launched from the International Space Station in 2014. The Doves on-orbit service would be initially be relatively brief due to atmospheric drag, but the low cost of manufacturing and rideshare launches would make possible rapid iteration of new generations. This iterative approach allowed Planet to rapidly improve the spacecraft capabilities and reliability while simultaneously serving customers, which was a wholly new approach in the industry. Latter generation Doves would be launched into higher orbits and see normal service lifetimes. More Flocks followed, including a recording-breaking launch of Flock 3p which consisted of 88 Dove satellites. From the total of over 500 spacecraft launched in the last decade, roughly 200 are currently active, representing continuous evolution in capabilities made possible by a cadence of 2-3 launches per year. By May 2015, Planet had raised a total of $183 million in financing, and used it to acquire Blackbridge, operator of the RapidEye five-satellite EO constellation. Its assets grew again in 2017 with the purchase of Terra Bella and its SkySat constellation of 15 EO cubesats from Google. The Skysat constellation was to grow over the next three years to a design total of 21 spacecraft, all of which are now operational and capturing 50cm data. Combined with the whole-Earth scanning of the Dove fleet, Planet can find an identify any change on the surface of our Planet. By imaging the entire Earth every day, Planet provides a revisit rate never before achieved. The imagery and data drawn from it is used to monitor farmers' fields, manage crops and improve yields. It enables defense and intelligence agencies to understand events, anticipate their impacts and respond effectively. Governments use it to map land use, manage resources and monitor urbanization. As our climate changes, it guides decision-makers in responding to drought, wildfire, flooding and climate-induced migration. The company's immense image archive also provides a global window into the past to illuminate the present and help predict the future. The remarkable success in less than a decade of the company founded by Marshall, Schingler and Boshuizen has helped inspire explosive growth in new Earth observation technologies, as well as space data analytics and new companies including ICEYE, Capella Space, Orbital Insight and Descartes Labs. Each successful innovation is adding to our understanding of the planet and better equips humanity to ensure a sustainable future. https://spacebq.org

Planet was founded in 2010 as Cosmogia by former NASA scientists Will Marshall, Robbie Schingler and Dr. Christopher Boshuizen. The three scientists-turned-entrepreneurs had a singular vision: to image the entire Earth every day to make changes visible, accessible and actionable. They were the first to deploy cubesats in a commercial capacity, and over the past decade, they succeeded in revolutionizing the Earth observation (EO) industry and expanding access to satellite-based data far beyond the traditional defense, intelligence and agricultural sectors. The co-founders planned to design and build their own cubesats called Doves for launch into low Earth orbit. Their first satellite was built in the archetypal California garage. Successful fundraising permitted them to launch two demonstration satellites, Dove 1 and 2, in April 2013 and two more in November, by which time the company had announced plans for a 28-satellite constellation called Flock-1. The flock was launched from the International Space Station in 2014. The Doves on-orbit service would be initially be relatively brief due to atmospheric drag, but the low cost of manufacturing and rideshare launches would make possible rapid iteration of new generations. This iterative approach allowed Planet to rapidly improve the spacecraft capabilities and reliability while simultaneously serving customers, which was a wholly new approach in the industry. Latter generation Doves would be launched into higher orbits and see normal service lifetimes. The remarkable success in less than a decade of the company founded by Marshall, Schingler and Boshuizen has helped inspire explosive growth in new Earth observation technologies, as well as space data analytics and new companies including ICEYE, Capella Space, Orbital Insight and Descartes Labs. Each successful innovation is adding to our understanding of the planet and better equips humanity to ensure a sustainable future.

On this week's dose, (2:26) we start things off with a discussion on Vint, a startup that allows you to invest in the emerging alternative asset class of fine wine and spirits. (7:45) Next, we talk about Howdy's $5M Series A extension, and how the Austin-based hybrid workforce platform is connecting top Latin American talent with US tech companies. (11:43) After that, we break down Sublime Systems' $40M Series A, and learn about how the company is revolutionizing cement production through a proprietary carbon-neutral approach. (16:04) Lastly, we close out this week's dose with a discourse on Capella Space's $60M growth round, and how the leading American satellite manufacturer and Earth observation company is keeping pace with increasing demand.Sources:https://vint.co/blog/Vint-Seed-Round-Announcementhttps://vint.co/blog/vint-how-it-workshttps://www.howdy.com/ https://www.prnewswire.com/news-releases/howdy-extends-series-a-by-5-million-bringing-total-to-18-million-following-a-full-rebrand-301717111.html http://sublime-systems.com/ https://www.businesswire.com/news/home/20230117005464/en/Sublime-Systems-Secures-40-Million-Series-A-to-Electrify-and-Scale-Decarbonized-Cement-Production https://www.capellaspace.com/https://www.prnewswire.com/news-releases/capella-space-raises-60m-in-growth-equity-from-the-united-states-innovative-technology-fund-to-expand-satellite-imaging-capacity-and-meet-rapidly-growing-customer-demand-301717388.htmlMusic Credit: Chapter One by Cole Bauer and Dean Keetonhttps://www.colebauer.com/https://www.instagram.com/deankeeton/?hl=en

Ep. 159: Bed Bath & Beyond reports wider-than-expected losses and there is a chance that they could be filing for bankruptcy. Babies R Us is attempting a comeback by opening a store in the American Dream mall. Coinbase is going to slash 20% of its workforce in a second major round of job cuts. Microsoft is reporting that they plan to invest $10 billion in ChatGPT. Finally, Capella Space raises $60 million fund by billionaire entertainment exec Thomas Tull.

Payam Banazadeh fell in love with space at a young age. He has since worked for NASA and has now launched his own space startup that has attracted over $170M in capital from investors. The venture, Capella Space has been financed by NightDragon Security, Cota Capital, Alumni Ventures, and DCVC.

On this episode of Satellite Superheroes, we're talking about Synthetic Aperture Radar ("SAR") Satellites with Payam Banazadeh, Founder and CEO of Capella Space. On any given day, 75% of the world is not visible by conventional optical imaging satellites. With Capella Space leading the way in SAR technology, 100% of the world is visible, providing near real-time images of changes taking place in our world. Enjoy the conversation. Payam Banazadeh's Contact Information: LinkedIn: https://www.linkedin.com/in/payamban/ (https://www.linkedin.com/in/payamban/) Company Website: https://www.capellaspace.com/ (https://www.capellaspace.com/) Company LinkedIn: https://www.linkedin.com/company/capella-space/ (https://www.linkedin.com/company/capella-space/)

Join us as we interview Payam Banazadeh, founder and CEO of Capella Space. Payam gives us a great overview of Capella and introduces us to their new Acadia generation of SAR satellites which brings increased resolution, capability, and efficiency for delivery to their customers. Tune in for the details. Capella Space is an information services company that provides on-demand, industry-leading, high-resolution synthetic aperture radar (SAR) Earth observation imagery. Through a constellation of small satellites, Capella provides easy access to frequent, timely, and flexible information affecting dozens of industries worldwide. Capella's high-resolution SAR satellites are matched with unparalleled infrastructure to deliver reliable global insights that sharpen our understanding of the changing world – improving decisions about commerce, conservation, and security on Earth. Learn more at www.capellaspace.com. Find out more about Project Geospatial and explore more content at www.projectgeospatial.com; including sponsorship opportunities. --- Support this podcast: https://anchor.fm/projectgeo/support

My guest this week is the founder & CEO of another prominent new space company – Payam Banazadeh from Capella Space. Capella is a remote sensing company that is using synthetic aperture radar (SAR) technology. Don't worry – we will explain what SAR is during the episode. The important summary: it allows you to see at night and through cloud cover. You can imagine that has interesting and important use cases. Payam will take us through those and many other things about Capella. Enjoy! Capella's job board: https://www.capellaspace.com/about-us/careers/ Opportunities to learn more about space business: Check out the new edX/EPFL Space Economy MOOC: https://www.edx.org/course/new-space-economy Raphael is designing a new, live-taught course. Join the mailing list to get updates and early access: https://jfx8zhjodpz.typeform.com/to/t0VSuhVD Raphael's introductory book on the space economy recently came out in its Portuguese translation: https://www.amazon.com/Para-Cima-Economia-Espacial-Portuguese-ebook/dp/B09X5WV3WC/ref=sr_1_1?crid=1ROKTHNSCZCRI The Space Business Podcast is sponsored by NanoAvionics. Support us at https://www.patreon.com/spacebusinesspodcast Follow the podcast on Twitter https://www.twitter.com/podcast_space Timestamps 0:00 Intro 2:50 Elevator pitch 4:07 Origin story 8:00 MH370 10:05 Geographic coverage 14:58 General use cases 19:10 Pricing 21:11 Government use cases 25:02 Commercial use cases 29:40 Cool things Capella detected 32:05 Hostile behavior 35:44 Satellite manufacturing & design 39:22 Sales process 46:27 Consolidation 48:52 Vision 50:49 Financing 55:27 Wrap-up: hiring, other things to do in the space sector, sci-fi

Looking at a satellite image of Ukraine online I realized it was from Capella Space – one of our Hacking for Defense student teams who now has 7 satellites in orbit. National Security is Now Dependent on Commercial Technology They're not the only startup in this fight. An entire wave of new startups and scaleups are providing satellite imagery and analysis, satellite communications, and unmanned aerial vehicles supporting the struggle.

Jeffrey and his team fear no cloud. Working with Capella Space to acquire cloud-piercing synthetic aperture radar (SAR) data, the MIIS team has been monitoring eternally-cloudy Novaya Zemlya, Russia, for evidence of Burevestnik nuclear-powered cruise missile tests. Evidence pointed to the Burevestnik test site being revived after the previous failures, and the team started utilizing radar returns to obviate the satellite-imagery-frustrating weather that plagues Russia's northern nuclear test ranges.  Jeffrey and Aaron discuss remote sensing technical education, and the value of teaching practical imagery interpretation, technical processing skills, and how to evaluate imagery at a non-technical level.  Previous Episodes: Discussing the tragic accident during the previous Burevestnik test. Links of Note: Zachary Cohen's CNN article on monitoring the Burevestnik. Support us over at Patreon.com/acwpodcast!

Vanesa Gomez Gonzalez is a ground software engineer with Capella Space. She has previously worked with NASA and also ESA as a software engineer. Vanessa has a background in software development.

There are *billions* of dollars' worth of invaluable imagery, information, and data available, for free from NASA, NOAA, ESA, and more but unfortunately, sometimes it can be hard to get to… and hard to use. The folks at Element 84, a software development firm specializing in large scale geospatial data systems and remote sensing believe that the more they can help make that data accessible and usable, the more we can learn about our planet and how it's changing.    “How hard can it be?” is a question Dan Pilone often asks his team. As the CEO & CTO of Dan oversees the architecture, design, and development for Element 84's commercial and government data clients including NASA, USGS, Stanford University School of Medicine, and Capella Space. “   About Element 84  “We are impatient optimists.”  “It's not magic, but it can *feel* like that - you can literally *see* the world changing, see storms, progress of wildfires, patterns of burning and growth, how to plan for changing water levels, how to help people impacted by disasters, or even just see some fantastic images of leaves changing in the fall.... Space gives us an incredible view of the planet we live on- and we want as many people to be able to take advantage of that unique view as possible.” – Dan Pilone   More at: www.element84.com    Dan mentions:   FunCube: https://amsat-uk.org/funcube/funcube-cubesat/   More about Dan Pilone:   ​Dan has supported NASA's Earth Observing System for over 15 years; currently acting as Chief Technologist for the NASA EOSDIS Evolution and Development contract. He has supported transitioning NASA's Petabyte scale archive to the cloud, contributed to metadata standards, led multiple working groups on data services and cloud architectures, authored studies on architecture and transition plans for cloud-native data management solutions, and helped shape software development processes for both government and commercial clients. Mr. Pilone has authored multiple books on software development and taught Software Engineering at Catholic University in Washington DC.

Pek Lum, co-founder, and CEO of Auransa believes that a lot fewer drugs would fail in Phase 2 clinical trials if they were tested on patients predisposed to respond. The problem is finding the sub-populations of likely high-responders in advance and matching them up with promising drug compounds. That’s Auransa's specialty.The Palo Alto, CA-based drug discovery startup, formerly known as Capella Biosciences, has a pipeline of novel compounds for treating cancer and other conditions identified through machine learning analysis of genomic data and other kinds of data. It’s closest to the clinical trial stage with a DNA-binding drug for liver cancer (AU-409) and is also working on drugs for prostate cancer and for protecting the heart against chemotherapy drugs. The company says it discovered AU-409 as part of a broad evaluation of data sets on a range of close to 30 diseases. The company’s discovery process uses a platform called the SMarTR Engine that uses hypothesis-free machine learning to identify druggable targets and compounds as well as likely high-responder patients. Lum  calls it “interrogating gene expression profiles to identify patient sub-populations.” The company believes this approach can identify unexpected connections between diverse molecular pathways to disease, and that it will lead to progress in drug development for intractable conditions with poorly understood biology, including cancer and autoimmune, metabolic, infectious, and neurological diseases.Lum co-founded Auransa with Viwat Visuthikraisee in 2014 and is the chief architect behind its technology. Before Auransa, she was VP of Product, VP of Solutions, and Chief Data Scientist at Ayasdi (now SymphonyAyasdiAI), a Stanford spinout known for building hypothesis-free machine learning models to detect patterns in business data. Before that, she spent 10 years as a scientific director at Rosetta Inpharmatics, a microarray and genomics company that was acquired by Merck. She has bachelor's and master's of science degrees in biochemistry from Hokkaido University in Japan and a Ph.D. in molecular biology from the University of Washington, where she studied yeast genetics.Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:• Launch the “Podcasts” app on your device. If you can’t find this app, swipe all the way to the left on your home screen until you’re on the Search page. Tap the search field at the top and type in “Podcasts.” Apple’s Podcasts app should show up in the search results.• Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.• Type MoneyBall Medicine into the search field and press the Search button.• In the search results, click on the MoneyBall Medicine logo.• On the next page, scroll down until you see the Ratings & Reviews section. Below that, you’ll see five purple stars.• Tap the stars to rate the show.• Scroll down a little farther. You’ll see a purple link saying “Write a Review.”• On the next screen, you’ll see the stars again. You can tap them to leave a rating if you haven’t already.• In the Title field, type a summary for your review.• In the Review field, type your review.• When you’re finished, click Send.• That’s it, you’re done. Thanks!TRANSCRIPTHarry Glorikian: I’m Harry Glorikian, and this is MoneyBall Medicine, the interview podcast where we meet researchers, entrepreneurs, and physicians who are using the power of data to improve patient health and make healthcare delivery more efficient. You can think of each episode as a new chapter in the never-ending audio version of my 2017 book, MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market. If you like the show, please do us a favor and leave a rating and review at Apple Podcasts.For every drug candidate that makes it all the way through the three phases of clinical trials to win FDA approval, there are about 20 others that fail along the way. Phase 2, where drug makers have to prove that a new drug is safer or more effective than existing treatments, is where a lot of drugs falter.But often, it’s not because the drugs don’t work. Sometimes it’s just because they weren’t tested on the right patients. Meaning, the people in the treatment group didn’t happen have the right genes or gene expression profiles to respond. If you could find enough patients who were likely high-responders and try your new drug just on them, your chances of approval might go way up. The tough part is identifying those subpopulations in advance and matching them up with promising drug compounds.That’s where a company like Auransa comes in. It’s a Palo Alto startup that has built an AI platform called the SMarTR Engine. The engine uses public datasets on gene expression to identify subtypes of molecular diseases and predict what kinds of compounds might work against specific subtypes. Auransa used the engine to discover a drug for liver cancer that’s about to enter clinical trials. And it’s licensing out other drugs it discovered for prostate cancer and for protecting the heart against the effects of cancer chemotherapy.Some of the ideas baked into the SMarTR Engine come from a sub-field of artificial intelligence called hypothesis-free machine learning. And joining us this week to explain exactly what that means is our guest Pek Lum. She’s a biochemist and molecular biologist who worked at the microarray maker Rosetta Inpharmatics and the software company Ayasdi before founding Auransa in 2014. And she says one of the real revolutions in drug development is that almost every disease can be divided up into molecular subtypes that can best be treated using targeted drugs.Harry Glorikian: Pek, welcome to the show.Pek Lum: Thank you. Pleasure to be here.Harry Glorikian: You know, I always try to ask this opening question when I start the show to give the listeners a good idea of of what your company does. But you guys are in in drug discovery. What tell us how people understand what is the basic approach that you guys have. And I'll get into the special sauce later. But what do you guys do in the drug discovery space?Pek Lum: No, that's a really great question in the sense that when we first started in about five years ago, we... I've always been in the drug discovery field in the sense that I worked for over 20 years ago at that time in a company called Rosetta Inpharmatics, which is really pushing the cutting edge of thinking about using molecular data. Right. And to solve the mysteries of biology. And I was extremely lucky to be one of the core members in when we were very small. And then that really kind of put me in the sense put me in the stage where I could think about more than just one gene. Right. Because the technology was just kind of getting really kind of I would say not rolling forward, like propelling forward, with microarrays.Harry Glorikian: Yes.Pek Lum: So I was part of the whole movement and it was really amazing to be kind of like, you know, in the show as it runs, so to speak. And so and then Merck bought us after we went public and worked for Merck and Co. for another eight years, really learning how technology, how we should apply technology, how we can apply technology, molecular data, RNA data, DNA data to a drug discovery pipeline. And really kind of figured out that there are many things that the pharmaceutical world does very well, but there are many things that it also fails in and that how can we do it better? So I've always been in the mindset of, when starting Auransa with my co-founder, How do we do it better? And not only just do it better, but do it very differently so that we can address the most, I would say critical problems. So Auransa is really a company started by us to address the problem of why drugs actually fail a lot when we go into a Phase II efficacy trial. Right. Is not like the drug is bad or toxic. And most of the time is you can find enough responders to make your clinical trial a success.Pek Lum: And that cause, I guess, drugs actually made to maybe against one target. You don't really think about the biology that much at the beginning or the biology responders. So Auransa was really created to think about first, the heterogeneity of the disease and the heterogeneity of patient response. So we start from looking at molecular data of the disease from the get go. We take RNA, is really the RNA world is coming back with the vaccines.Harry Glorikian: Right.Pek Lum: And the RNA has always been fascinating because it tells you about the activity of the cell, of a normal cell versus a disease cell. So we use RNA transcriptomes right, transcriptomics to study the biology and the heterogeneity. So our algorithms, there are many algorithms, one of the first algorithms of the engine is really to look at the biology of heterogeneity, whether we can subdivide a disease into more homogeneous categories before doing anything.Harry Glorikian: Right. Yeah, I remember when, because when I was at Applied Biosystems, I remember Applied Biosystems, Affymetrix and then Stephen Friend starting this and like, you know, it was all starting back then. And I want to say we sort of had an idea of what we were doing, but compared to now, it's like, wow, how naive we were back then compared to how much this whole space has evolved. And it's interesting you mention, you know, RNA and its activity because in a couple of weeks, I'm actually going to be talking to a spatial genomics company so that you get a better idea from a visual standpoint of which cells are actually activating and which aren't.Harry Glorikian: But so, you've got an interesting professional career, and I say that because you were working at a big data analytics company for a while that was utilizing an approach that was hypothesis-free machine learning, where the machine was sort of identifying unique or aspects that you should be paying attention to. Maybe that it was seeing that instead of you going in there saying, let's just look over here, you could see what the machine was seeing for you. How much can you tell us a little bit about that experience? And then how did that influence what you're doing now? Because I have to believe that they superimpose at some level.Pek Lum: Right. I think, you know, ever since my first job at Rosetta and then my subsequent jobs really kind of culminated into this into this tech, as you see today. Right. All this experience and certainly experience while being a founding member of a small team at that time of Ayasdi, which is the software company, has been also an eye-opening experience for me because we were trying to create, using a very old mathematical idea called topology, or TDA, really start to figure out whether there's maybe there's some things that can't be learned. Right. And so typical machine learning methods need a training set or a test. But there are just some things where you don't really know what the ground truth is. So how do you do that? So that's the idea of like I say, the hypothesis-free approach. And the approach that that that the tech company, the software company that we built is really around the idea that not everything can be learned. But you can actually adapt some very interesting ideas around a hypothesis-free approach and then use it in a machine learning AI framework. So I definitely have been influenced by that thinking, you know, as I as we built the software.Harry Glorikian: Right.Pek Lum: And also, when we were Rosetta, we were generating in parallel, data on thousands of genes. And often at that time we were called, "Oh, you're just going fishing," you know, but fishing is not a bad idea because you don't really know which part of the ocean you need to go to catch your Blue Marlin, for example, right?Harry Glorikian: Yeah, no, no, absolutely.Pek Lum: Fish a little bit, not the whole ocean, but, you know, to get some, I would say, boundaries. Right. So in that sense, to me, a hypothesis-free approach gives you the boundaries where you can look. So, you know, so the experience, definitely the idea that you can use methods or thinking, algorithms, that could help you in a field where you do not know the ground truth. Like patient heterogeneity, I would say nobody really can pinpoint and say, OK, I can say that, oh, this is THE subtype, these are THE markers. And therefore, I'm going to go after this. And there are many. I guess, for example, you can think of a Herceptin as a great example, right, but when you first started, you know, it was like, wow, OK, you're going to go after a target. And then the idea of really kind of subtyping breast cancer, you know, I don't know, 20, 30 years ago. Right. And we're still learning about, you know, in a patient heterogeneity and we're just beginning to scratch the surface. So for Auransa, we wanted to use a method very much like the thinking that and the idea that we had, you know, when we were when I was at Ayasdi, is that you could search with some parameters, you know, a very complex space without needing to say, this is my hypothesis. This is that one gene, because we all know that if you have a target, you know ... to have to respond you need the target. But if you have the target, it doesn't mean you're going to respond. Because things below the target or above the target are much more complex than that.Harry Glorikian: Correct. And I always feel that there's, you know, I always call them low hanging fruit. Like the first one is, OK, well, it's either luck or skill, but I got to one level. But then you start to see people that are not responding. So that means something else is going on and there's subtypes. Right. So it's funny how we always also call it "rare diseases" in these smaller population. I'm pretty convinced that at some point everything is going to be a rare disease. Right. Because of the subtypes that we're going to start to see. I mean, even we're seeing in a neurological now, or Alzheimer's. There's subtypes of Alzheimer’s. No! Really? Shocking. Amazing to me that there's subtypes. Right. We've been dealing with this for ages. And I do believe that these technologies are so good at highlighting something where a human might not have seen it, might not have understood it. You know, I was I was interviewing actually I just posted it today on imaging and agriculture. And they were saying that sometimes the machine sees things that we don't fully understand how it sees it, but it sees it and points it out, which allows us now to dig into it and be able to sort of identify what that unique feature is that the machine has pulled out. I'm not sure I want drug discovery and drugs being based on something we don't fully understand, but the machine highlighting something for us that then we can go dig into, I think is an interesting greenfield space that that we need to explore more.Pek Lum: Right. I think you're absolutely right. You know, when we first started Auransa, that was the idea that we had. And then my co-founder and I thought, what if we find like hundreds of subtypes? We're never going to be able to make a drug again a hundred subtypes. So let's hope we find a small enough number of buckets that we can say this is approximately what it looks like, to be able to be practical to find drugs against those subtypes. So when we talk about subtypes, we are talking about you're absolutely right, it's like a leaf on a tree and that we have to cut it off at one point. Enough that things that, OK, this is homogeneous enough that actually makes sense out of it. And that's where the engine, that's what the engine does. Basically, it takes data, very, very complex data, things that we could never figure that out ourselves and say this approximately five, six buckets. So we've actually not found hundreds of subtypes, otherwise we probably would not have started Auransan, because it would have been impossible. But instead, we find n of one, but maybe a five to seven subtypes at most. That is enough for us to say, the machine says, OK, it is homogeneous enough, go for this. So that's kind of where we are, where we start at Auransa. And I think that's an important concept because people often thought about precision medicine as being, oh, I'm going to make a medicine for you and you only. But actually you could learn from, say, breast cancer, and that's approximately people with estrogen-receptor-positive tumors. And then you will likely respond to a drug like Tamoxifen. And even though we know that the response rate is only about, I think maybe 30, 40 percent. Right. But that's really good. At least at this poibt. So that's where we how we think about the engine as a shining light on a homogeneous enough population that we can actually make a drug against that.Harry Glorikian: Yeah. So that sort of leads us into you have this technology that you've termed SMarTR, S-M-A-R-T-R engine. Right. What does that stand for?Pek Lum: You know, that's my one of my rare occasion where I put my marketing hat on. I don't like marketing all. And we so and you notice the Mar is big-M, little-a-r. So S is for Subpopulation. Markers. Targets. And Redefining. Because I needed it to be Smartr.Harry Glorikian: Ok, ok. So and when you like when you've described this in the papers that I've looked at it, it's a machine learning mathematical statistical approaches, highly automated and totally runs in the cloud. So can you give us a little more color on the sort of the highly automated, and why is that so important?Pek Lum: Right. It's important because it comes from my own experience of working with, like, amazingly talented implementations and data scientist at the at Merck or I know how it goes where biologists will often ask them for something and they would run their magic and they'd give us an Excel sheet or a PowerPoint. Right. It's always a one-off one of those and one of that because you know, biologists are kind of one-off. So the idea of of us building this engine is not just equipping it with algorithms. So first of all, we don't have one algorithm, a hammer looking for a nail. We have a problem to solve. The problem is how to find novel drugs, drugs that people have never thought about, for patient populations that will respond.Pek Lum: So with that in mind, we built a pipeline of algorithms that starting from thinking about heterogeneity, to understanding preclinical models that reflect the biology of human subtypes, to predicting drugs and targets for those, and getting biomarkers for the patients when we go to the clinic. And we have different algorithms for each step of the pathway. So instead of having my team do a one-off thing, we know that if we don't do good software engineering it's going to be problematic because first it's going to take a really long time. This will be kind of higgledy piggledy in Excel sheets and we might be able to solve one thing. But to do this as a platform and as a pipeline builder, it would be impossible without good engineering practices. So we wanted to put this in, like I say, in a framework where everything is connected, so where it gets to run faster and faster through better algorithms, through better software engineering. And this really kind of came from my experience to at Ayasdi, a software engineering, a software firm. And also my co-founder who is a physicist and a software engineer, that we need to have good software practices. So what we did was we built first. We don't want any servers. Everything is done on AWS and is done in modules. So we create algorithms for each part of the pipeline, of the in silico pipeline. And then we have in such a way that when we take data in, when we ingest data, that we also automate it, and then by the time it ingest data and it spits out, I would say, what subtypes of disease, what biomarkers could be used in the clinic, what targets are interesting to you, what compounds from our digital library of compounds may be effective for that. Everything is more or less connected and could be done up in the cloud and now it finishes in about 24 hours.Harry Glorikian: When do humans look at it to say hmmm, makes sense. Or maybe we need to tweak the model a little. Right. Because it's not making sense. When does that happen?Pek Lum: So we, it happens at several steps. So within our engine we actually have benchmarks in there that we run periodically. You know, for example we have about about eight to ten data sets that we have for breast cancer, thousands of patient tumors. And we know approximately that it should be discovering, and it has discovered ER+ flavored subtypes, ERBB2, HER2+ subtypes, triple negative subtypes. So that is kind of like the rails that we put into our engine as well to make sure that when we actually do tweak an algorithm, it still has its wheels. But what we do is at this point, we generate out all the in-between data, but it's kept on the cloud. And once it's up, when it outputs the the list of things, the biologists actually, I would say the biologists with a knack for computation, we look at it and I myself look at it. I love to do data analysis in my spare time when I'm not doing CEO stuff. And we can see that we will look at once it's done that it also allows you...Ok, so this is an interesting one. The engine on the cloud outputs all of this. And right now, let's say my CSO, who is not a computational person, or me, or whoever really would be kind of a big pain to kind of go up and install the stuff and look at the things, some things you can't see. So what we did as a company is to build another kind of software, which is the visualization software on top of that.Pek Lum: So we have on our other end a visualization software that we call Polo because it's exploring that basically connects everything the SMarTR engine has done into something that's visualizable. It has a URL, we go to it and let's say, for example, my CSO wants to know, OK, the last one you did on head and neck cancer, you know, how many subtypes did you find? What is the biology, what's the pathway? And it could do all of that by him just going then looking at things. Or he can actually type in his favorite gene and then see what the favorite gene actually is predicted for how it behaves across over 30 diseases, and you can do that all at his fingertips, so we have that part of the engine as well, which is not the engine. We call it Polo, which is our visualization platform.Harry Glorikian: Right. It's funny because one of the first times I interviewed Berg Pharma and they were talking about their system, I was like, if you put on a pair of VR glasses, could you see the interconnectivity and be able to look in a spatial.... I was on another planet at the time, but it was a lot of fun sort of thinking about how you could visualize how these things interact to make it easy. Because human beings I mean, you see a picture. Somehow we're able to process a picture a lot faster than all this individual data. I think it... I just slow down. I rather look at a visual if it's possible.Pek Lum: It is so important because, you know, even though the engine is extremely powerful now, takes it 24 hours to finish from data input to kind of spitting out this information that we need. Visualization and also like the interpretation and just kind of making sure kind of like the human intelligence. Can I keep an eye on things. The visualization platform is so, so important. That's why I feel like that we did the right thing in making and taking time, putting a bit of resources to make this visualization platform for our preclinical team who actually then needs to look at it and go, OK, these are the drugs that are that are predicted by the engine. Can we actually have an analog of it or does it have development legs? Does it make sense? Does the biology makes sense. And so now we're basically connected everything. So you can click on a, you can find a drug in a database and it will pop up, you know, the structure and then it will tell you, hey, this one has a furan ring. So maybe you might want to be careful about that. This one has a reactive oxygen moiety. You might want to be careful about that. As we grew the visualization platform, we got feedback from the users. So we put more and more things in there, such that now it has a little visualization module that you can go to. And if you ever want to know something, I can just, I don't have to email my data scientist at 1:00 am in the morning saying, hey, can you send me that Excel sheet that has that that particular thing on it that I want to know from two weeks ago? I can just go to Auransa's Polo, right? As long as I have wi-fi. Right. And be able to be self-sufficient and look at things and then ask them questions if things look weird or, you know, talk to my CEO and say, hey, look at this. This is actually pretty interesting. And this one gets accessed by anybody in Auransa as long as you have Wi-Fi.Harry Glorikian: So so it's software development and drug development at the same time. Right. It's interesting because I always think to myself, if we ever, like, went back and thought about how to redo pharma, you'd probably tear apart the existing big pharma. Other than maybe the marketing group, right, marketing and sales group, you tear apart the rest of it and build it completely differently from the ground up? It was funny, I was talking to someone yesterday at a financial firm, a good friend of mine, and it's her new job and she's like, my job is to fully automate the back to the back end and the middle and go from 200 people down to 30 people because we're fully automating it. I'm like, well, that sounds really cool. I'm not really thrilled about losing the other 170 people. But with today's technology, you can make some of these processes much more automated and efficient. So where do you get your data sets that you feed your programs?Pek Lum: Yeah, let me tell you this. We are asked this a lot of times. And just kind of coming back again for my background as an RNA person. Right. One thing that I think NIH and CBI did really well over 20 years ago is to say, guys, now we no longer doing a one gene thing. We have microarrays and we're going to have sequencing. There's going to be a ton of data. We need to start a national database. Right. And it will enable, for anybody that publishes, to put the data into a coherent place. And even with big projects like TCGA, they need things that could be accessed. Right. So I think it is really cool that we have this kind of, I would say, repository. That unfortunately is not used by a lot of people because, you know, everything goes in. That's a ton of heterogeneity. So when we first started the company, before we even started the company, we thought about, OK, where is it that we can get data? We could spend billions of dollars generating data on cells, pristine data, but then it would never represent what's in the clinical trials without what's out there in the human the human world, which is the wild, wild west. Right. Heterogeneity is abundant. So we thought, aha, a repository like, you know, like GEO, the Gene Expression Omnibus, right, and ANBO or TCGA allows this kind of heterogeneity to come in and allows us the opportunity to actually use the algorithms which actually have algorithms that we look for. We actually use to look for heterogeneity and put them into homogeneity. These kind of data sets. So we love the public data sets. So because it's free, is generated by a ton of money. It is just sitting there and it's got heterogeneity like nobody's business. Like you could find a cohort of patients that came from India, a cohort of patients that came from North Carolina, and group of patients that came from Singapore and from different places in the US and different platforms. So because the algorithms at first that studied heterogeneity is actually, I would say, platform independent, platform agnostic, we don't use things that are done 20 years ago. They were done yesterday. And what we do is we look at each one of them individually and then we look for recurrent biological signals. So that's the idea behind looking for true signals, because people always say, you go fishing, you may be getting junk out. Right?Pek Lum: So let's say, for example, we go to, the engine points to a spot in the sea, in the ocean, and five people go, then you're always fishing out the same thing, the Blue Marlin, then you know that there is something there. So what we do is we take each data set, runs it through an engine and say these are the subtypes that I find. It does the same thing again in another data set and say these are the things that I find. And then it looks for recurrence signals, which is if you are a artifact that came from this one lab over here, or some kind of something that is unique to this other code over there, you can never find it to be recurrent. And that's a very weird, systematic bias, you know, so so because of that, we are able to then very quickly, I would say, get the wheat and throw away the chaff. Right. And basically by just looking by the engine, looking at looking for recurring signals. So public data sets is like a a treasure trove for Auransa because we can use it.Harry Glorikian: So you guys use your engine to I think you identified something unexpected, a correlation between plant-derived flavonoid compound and the heart. I think it was, you found that it helps mitigate toxic effects in a chemotherapy drug, you know. Can you say more about how the system figured that out, because that sounds not necessarily like a brand-new opportunity, but identifying something that works in a different way than what we thought originally.Pek Lum: Right, exactly. So in our digital library, let me explain a little bit about that. We have collected probably close to half a million gene expression profiles. So it's all RNA gene expression based, representing about 22,000 unique compounds. And these are things that we might generate ourselves or they are in the public domain. So any compound that has seen a live cell is fair game to our algorithms. So basically you put a compound, could be Merck's compound, could be a tool compound, could be a natural compound, could be a compound from somewhere. And it's put on a cell and gene expression was captured. And those are the profiles or the signatures that we gather. And then the idea is that, because remember, we have this part of the engine where we say we're going to take the biology and study it and then we're going to match it or we're going to look for compounds or targets. When you knock it down, who's gene expression actually goes the opposite way of the the disease. Now, this is a concept that is not new, right. In the sense that over 20 years ago, I think Rosetta probably was one of the first companies that say, look, if you have a compound that affects the living cell and it affects biology in a way that is the opposite of your disease, it's a good thing. Right thing. So that's the concept. But, you know, the idea then is to do this in such a way that you don't have to test thousands of compounds.Harry Glorikian: Right.Pek Lum: That is accurate enough for you to test a handful. And that's what we do. And by putting the heterogeneity concept together with this is something extremely novel and extremely important for the engine. And so with this kind of toxicity is actually an interesting story. We have a bunch of friends who are spun off a company from Stanford and they were building cardiomyocytes from IPS cells to print stem cells. And they wanted to do work with us, saying that why do we work together on a cool project? We were just starting out together and we thought about this project where it is a highly unmet medical need, even though chemotherapy works extremely well. Anthracyclines, it actually takes heart, takes a toll. There is toxicity and is it's a known fact. And there's only one drug in the market and a very old drug in the market today. And there is not much attention paid to this very critical aspect. So we thought we can marry the engine. At that time were starting up with oncology. We still we still are in oncology, and they were in cardiomyocytes. So we decided to tackle this extremely difficult biology where we say, what is a how does chemotherapy affect heart cells and what does the toxicity look like? So the engine took all kinds of data sets, heart failure data sets, its key stroke and cells that's been treated with anthracyclines. So a ton of data and look for homogeneity and signals of the of the toxicity.Pek Lum: So this is a little bit different from the disease biology, but it is studying toxicity. And we then ask the engine to find compounds that we have in our digital library, that says that what is the, I would say the biology of these compounds when they hit a living cell that goes the opposite way of the toxicity. And that's how we found, actually we gave the company probably about seven, I forget, maybe seven to 10 compounds to test. The one thing that's really great about our engine is that you don't have to test thousands of compounds and it's not a screen because you screened it in silico. And then it would choose a small number of compounds, usually not usually fewer than 30. And then we able to test and get at least a handful of those that are worth looking into and have what they call development legs. So this I would say this IPSC cardiomyocyte system is actually quite complex. You can imagine that to screen a drug that protects against, say, doxorubicin is going to be a pretty complicated screen that can probably very, very hard to do in a high throughput screen because you have to hit it with docs and then you have to hit it with the compounds you want to test and see whether it protects against a readout that is quite complex, like the beating heart.Pek Lum: And so we give them about, I think, seven to 10 and actually four of them came out to be positive. Pretty amazing. Out of the four, one of them, the engine, noticed that it belonged to a family of other compounds that looked like it. So so that was really another hint for the the developers to say, oh, the developers I mean, drug developers to say, this is interesting. So we tested then a whole bunch of compounds that look like it. And then one of them became the lead compound that we actually licensed to a a pharma company in China to develop it for the Chinese market first. We still have the worldwide rights to that. So that's how we tackled toxicity. And I think you might have read about another project with Genentech, actually, Roche. We have a poster together. And that is also the same idea, that if you can do that for cardio tox, perhaps you can do it for other kinds of toxicity. And one of them is actually GI tox, which is a very common toxicity. Some of them are rate limiting, you might have to pull a drug from clinical trials because there's too much GI tox or it could be rate limiting to that. So we are tackling the idea that you can use to use machine, our engine, to create drugs for an adjuvant for a disease, a life-saving drug that otherwise could not be used properly, for example. So that's kind of one way that we have to use the engine just starting from this little project that we did with the spin out, basically.Pek Lum: So basically, you're sort of, the engine is going in two directions. One is to identify new things, but one is to, I dare say, repurpose something for something that wasn't expected or wasn't known.Pek Lum: That is right. Because it doesn't really know. It doesn't read papers and know is it's a repurposed drug or something. You just put in it basically, you know, the gene expression profiles or patterns of all kinds of drugs. And then from there, as a company, we decided on two things. We want to be practical, right. And then we want to find novel things, things that, and it doesn't matter where that comes from, as long as the drug could be used to do something novel or something that nobody has ever thought of or it could help save lives, we go for it. However, you know, we could find something. We were lucky to find something like this flavanol that has never been in humans before. So it still qualifies as an NCE, actually, and because it's just a natural compound. So so in that sense, I would say maybe is not repurposing, but it's repositioning. I don't know from it being a natural compound to being something maybe useful for heart protection. Pek Lum: Now for our liver cancer compound, it is a total, totally brand-new compound. The initial compound that the engine found is actually a very, very old drug. But it was just a completely different thing and definitely not suitable for cancer patients the way it is delivered.Harry Glorikian: This is the AU 409?Pek Lum: Correct? Entirely new entity. New composition of matter. But the engine gave us the first lead, the first hit, and told us that we analyzed over a thousand liver tumors and probably over a thousand normal controls, found actually three subtypes, two of them the main subtypes and very interesting biology. And the engine predicted this compound that it thinks will work on both big subtypes. We thought this is interesting. But we look at the compound. You know, it's been in humans. It's been used. It's an old drug. But it could never be given to a cancer patient. And so and so our team, our preclinical development team basically took that and say, can we actually make this into a cancer drug? So we evaluated that and thought, yes, we can. So we can basically, we analogged it. It becomes a new chemical. Now it's water-soluble. We want to be given as a pill once a day for liver cancer patients. So so that's how we kind of, as each of the drug programs move forward, we make a decision, the humans make a decision, after the leadds us to that and say can we make it into a drug that can be given to patients?Harry Glorikian: So where does that program stand now? I mean, where is it in its process or its in its lifecycle?Pek Lum: Yeah, it's actually we are GMP manufacturing right now. It's already gone through a pre-IND meeting, so it's very exciting for us and it's got a superior toxicity profile. We think it's very well tolerated, let's put it that way. It could be very well tolerated. And it's it's at the the stage where we are in the GMP manufacturing phase, thinking about how to make that product and so on.Harry Glorikian: So that that begs the question of do you see the company as a standalone pharma company? Do you see it as a drug discovery partner that that works with somebody else? I'm you know, it's interesting because I've talked to other groups and they start out one place and then they they migrate someplace else. Right. Because they want the bigger opportunities. And so I'm wondering where you guys are.Pek Lum: Yeah, we've always wanted to be, I say we describe ourselves as a technology company, deep tech company with the killer app. And the killer app is drug discovery and development especially. And we've always thought about our company as a platform company, and we were never shy about partnering with others from the get go. So with our O18 our team, which is a cardioprotection drug, we out-licensed that really early, and it's found a home and now is being developed. And then we moved on to our liver cancer product, which we brought a little bit further. Now it's in GMP manufacturing. And we're actually looking for partners for that. And we have a prostate cancer compound in lead optimization that will probably pan out as well. So we see ourselves as being partners. Either we co-develop, or we out-license it and maybe one day, hopefully not too far in the future, we might bring one or two of our favorite ones into later stage clinical trials. But we are not shy about partnering at different stages. So we are going to be opportunistic because we really have a lot to offer. And also one thing that we've been talking to other partners, entrepreneurs, is that using our engine to form actually other companies, to really make sure the engine gets used and properly leveraged for other things that Auransa may not do because we just can't do everything.Harry Glorikian: No, that's impossible. And the conversation I have with entrepreneurs all the time, yes, I know you can do it all, but can we just pick one thing and get it across the finish line? And it also dramatically changes valuation, being able to get what I have people that tell me, you know, one of these days I have to see one of these A.I. systems get something out. And I always tell them, like, if you wait that long, you'll be too late.Harry Glorikian: So here's an interesting question, though. And jumping back to almost the beginning. The company was named Capella. And you change the name to Auransa.Pek Lum: That's right.Harry Glorikian: And so what's the story behind that? Gosh, you know.Harry Glorikian: When somebody woke up one morning and said, I don't like that name.Pek Lum: It's actually pretty funny. So we so we like to go to the Palo Alto foothills and watch the stars with the kids. And then one day we saw Capella. From afar, you look at it, it's actually one star. You look at closer, it's two stars. Then closer, it's four stars. It's pretty remarkable. And I thought, OK, we should name it Capella Biosciences. Thinking we are the only ones on the planet that are named. So we got Capella Biosciences and then probably, we never actually had a website yet. So we were just kind of chugging along early days and then we realized that there was a Capella Bioscience across the pond in the U.K. We said what? How can somebody be named Capella Bioscience without an S? So I actually called up the company and said, “Hey, we are like your twin across the pond. We're doing something a little different, actually completely different. But you are Capella Bioscience and I am Capella Biosciences. What should we do?” And they're like, “Well, we like the name.” We're like, “Well, we like it too.” So we kind of waited for a while. And but in the meantime, I started to think about a new name in case we need to change it. And then we realized that one day we were trying to buy a table, one of those cool tables that you can use as a ping pong table that also doubles as a as a conference room table. So we called up this New York City company and they said, oh, yeah, when are you going to launch the rockets into space. We're like what? So apparently, there's a Capella Space.Harry Glorikian: Yeah, OK.Pek Lum: Well, that's the last straw, because we get people tweeting about using our Twitter handle for something else. And so it's just a mess. So we've been thinking about this other name, and I thought this is a good name. Au means gold. And ansa is actually Latin for opportunity, which we found out. So we're like oh, golden opportunity. Golden answer. That kind of fits into the platform idea. Auransa sounds feminine. I like it. I'm female CEO. And I can get auransa.com. Nobody has Auransa. So that is how Auransa came to be.Harry Glorikian: Well, you got to love the…I love the Latin dictionary when I'm going through there and when I'm looking for names for a company, I've done that a number of times, so. Well, I can only wish you incredible success in your journey and what you're doing, it's such a fascinating area. I mean, I always have this dream that one day everybody is going to share all this data and we're going to move even faster. But I'm not holding my breath on that one when it comes to private companies. But it was great to talk to you. And I hope that we can continue the conversation in the future and watch the watch the progression of the company.Pek Lum: Thank you, Harry. This has been really fun.Harry Glorikian: That’s it for this week’s show. We’ve made more than 50 episodes of MoneyBall Medicine, and you can find all of them at glorikian.com under the tab “Podcast.” You can follow me on Twitter at hglorikian. If you like the show, please do us a favor and leave a rating and review at Apple Podcasts. Thanks, and we’ll be back soon with our next interview.  

New Content, Sunburst Analysis, Shipping Alert Shipping, Malwarebytes RDP Ports, DJI Badlist, Sophos ReversingLabs Samples, Capella Space, Technology News, Human News, Ideas Trends & Analysis, Discovery, Recommendations, and the Weekly Aphorism… Support the show: https://danielmiessler.com/support/ See omnystudio.com/listener for privacy information.

Ep. 9 do TDCast! Bem-vind@s ao Ep. 9 do TDCast! E neste episódio nós vamos falar sobre: - lançamento de satélites - satélites que conseguem enxergar sem luz - drones feitos de abacaxi - novas regras para drones nos Estados Unidos - e aplicativo de combate a Covid-19   Links: Satélite Amazonia-1 - https://mundogeo.com/2021/01/07/satelite-amazonia-1-passa-por-primeira-inspecao-na-india/ Missão Amazonia - http://www.inpe.br/amazonia1/ Satélites de madeira  - https://g1.globo.com/economia/tecnologia/noticia/2020/12/30/japao-desenvolve-satelites-de-madeira-para-eliminar-lixo-espacial.ghtml Satélite Capella Space - https://gizmodo.uol.com.br/satelite-alta-resolucao-eua-vigilancia/ Site Capella Space - https://www.capellaspace.com/ Drones com folhas de abacaxi - https://www.tecmundo.com.br/produto/209008-pesquisadores-transformam-folhas-abacaxi-pecas-drones.htm Novas regras para drones nos EUA - https://www.cnnbrasil.com.br/business/2020/12/28/luzes-e-voo-noturno-agencia-dos-eua-aprova-regras-para-entrega-por-drones Risco a privacidade das novas regras - https://olhardigital.com.br/2021/01/05/seguranca/novas-regras-para-drones-trazem-riscos-a-privacidade-de-americanos/ Mapas de solo da Embrapa - https://geoportal.cprm.gov.br/pronasolos/ App Covid-19 RJ - https://canaltech.com.br/saude/prefeitura-do-rio-vai-lancar-app-para-notificacao-e-informacoes-sobre-a-covid-19-176958/ App What3Words - https://what3words.com/about-us/ Palavras do desafio: Cais/Baralhos/Rebaixando Músicas:  Big Hands Ella Vater Cheerleader The Machine Assembly Fugetaboutit Late Truth Find Your Way Star Align

New Content, Sunburst Analysis, Shipping Alert Shipping, Malwarebytes RDP Ports, DJI Badlist, Sophos ReversingLabs Samples, Capella Space, Technology News, Human News, Ideas Trends & Analysis, Discovery, Recommendations, and the Weekly Aphorism…

The Fix This team chatted with retired General Clint Crosier, the director of aerospace and satellite business at Amazon Web Services (AWS). Clint shares his thoughts on how the AWS Cloud will help customers approach challenges differently in order to deliver on their missions. From being customer obsessed to discovering more about life on Earth through space exploration, Clint discusses how AWS will help customers explore the new frontier. Next, the team talked to Payam Banazadeh, founder and chief executive officer of Capella Space. Payam explains how Capella’s Earth observation satellites use AWS Ground Station to speed up the process of downlinking data and delivering it to decision makers.

December 17, 2020 - Daily NewsSupport the show (https://www.patreon.com/theoneminutenews)

Twitter- @bluehelmco Instagram - @bluehelmco (https://www.bluehelmco.com) Sponsor- (https://hopeschest.com) Headlines- 1) Space Development Agency seeks bids for launch services for 28 satellites a.(https://spacenews.com/space-development-agency-seeks-bids-for-launch-services-for-28-satellites/) 2) Boeing astronaut Chris Ferguson withdraws from Starliner test flight a.(https://spacenews.com/boeing-astronaut-chris-ferguson-withdraws-from-starliner-test-flight/) 3) Momentus to go public with Stable Road Acquisition Corp. a.(https://spacenews.com/momentus-to-go-public/) 4) Capella Space unveils first radar satellite images a.(https://spacenews.com/capella-sequoia-first-imagery/) 5) Schedule is king for C-band replacement satellites a.(https://spacenews.com/speedy-satellite-manufacturing/) Law and policy- 1) House space subcommittee chair still seeking NASA plan for 2024 lunar landing a.(https://spacenews.com/house-space-subcommittee-chair-still-seeking-nasa-plan-for-2024-lunar-landing/) ** WHAT’S HAPPENING IN SPACE POLICY Oct 4th—Oct 10th, 2020 a. (https://spacepolicyonline.com/news/whats-happening-in-space-policy-october-4-10-2020/) Events- 1)September 2020 Space Calendar of Events a.(http://spaceref.com/calendar/) 2) Launch Calendar a. (https://www.space.com/32286-space-calendar.html 3)Draconid meteor shower a.(https://www.space.com/38390-draconid-meteor-shower-guide.html)

The NSV September Episode is all about radar satellites and its applications. We invited a very special guest who helped to shape and grow the SAR Satellite Industry in the 90s and 2000s in Germany like no other: Joerg F. Herrmann, former founding CEO of the TerraSAR-X services entity Infoterra, Sr. business development executive at Airbus Defense and now Sr. VP at Capella Space. From first endeavors to the first wave of commercialization of SAR. Join us for a conversation about the creation of Germany's first Digital Elevation Model in early 2000 to TerraSAR and TandemSAR as well as differences of working for a U.S. start-up compared to his time in Germany, building the TerraSAR. We explore the question: Why is Germany currently lacking a private German SAR constellation with the ambition of Capella Space, Iceye, PredaSAR (U.S.) or Synspective (Japan) or a leading new space hardware startup? ...and even dare to ask: Is there an underutilization of SAR technology?

CosmiQ’s Jake Shermeyer and Daniel Hogan are joined by Capella Space’s Jason Brown and IEEE Geoscience and Remote Sensing’s (GRSS) Ronny Hänsch to once again discuss the SpaceNet 6 Dataset and post-challenge experiments. Learn more about data fusion and deep learning approaches that work to blend synthetic aperture radar (SAR) and optical imagery. Additionally, the podcast also explores the value of frequent SAR revisits that can be beneficial for foundational mapping applications. Finally, the group discusses CosmiQ’s new addition to the Solaris python package: a multi-modal pre-processing library and a new API called ‘PipeSegment’ for seamlessly stringing together different operations.SpaceNet is a nonprofit made possible by co-founder and managing partner, CosmiQ Works; co-founder and co-chair, Maxar Technologies; and all the other Partners: Amazon Web Services (AWS), Capella Space, Topcoder, IEEE Geoscience and Remote Sensing (GRSS), the National Geospatial-Intelligence Agency, and Planet.  

SpaceNet is a non-profit dedicated to accelerating open source, applied research in geospatial machine learning. In this episode, CosmiQ’s Ryan Lewis, Jake Shermeyer, and Daniel Hogan discuss the SpaceNet 6 Challenge where participants were asked to automatically extract building footprints with computer vision and AI algorithms using a combination of synthetic aperture radar (SAR) and electro-optical imagery. Hear about the challenge’s winning artificial intelligence models and the tradeoff between inference speed and model performance. SpaceNet is made possible by co-founder and managing partner, CosmiQ Works; co-founder and co-chair, Maxar Technologies; and all the other Partners: Amazon Web Services (AWS), Capella Space, Topcoder, IEEE Geoscience and Remote Sensing (GRSS), the National Geospatial-Intelligence Agency, and Planet.Learn more at www.spacenet.ai, and at the DownLinQ (https://medium.com/the-downlinq)

Despite its application to myriad humanitarian and civil use cases, automated road network extraction from overhead satellite imagery remains quite challenging. However, the SpaceNet 5 challenge made significant progress in this field with top participants being able to extract both road networks and speed/travel time estimates for each roadway. On today’s pod, CosmiQ’s Ryan Lewis and Dr. Adam Van Etten explore the challenge’s unique dataset and geographic diversity over time, the winning models, and the tradeoff between inference speed and model performance. SpaceNet is a non-profit LLC co-founded and managed by In-Q-Tel's CosmiQ Works in collaboration Maxar Technologies, a co-founder, and the other SpaceNet Partners including AWS, Intel AI, Topcoder, Capella Space, IEEE GRSS, The National Geospatial-Intelligence Agency (NGA), and Planet.

In this segment, Adam Simmons Interviews Jake Shermeyer, Research Scientist at CosmiQ Works. The discussion is focused around the upcoming SpaceNet 6 Challenge, SAR Datasets used, and Jakes's perspective on current imagery technology. SpaceNet LLC is a nonprofit organization dedicated to accelerating open source, artificial intelligence applied research for geospatial applications, specifically foundational mapping (i.e. building footprint & road network detection). SpaceNet is run in collaboration with CosmiQ Works, Maxar Technologies, Intel AI, Amazon Web Services (AWS), Capella Space, Topcoder, and IEEE GRSS. Support Us! Enjoy listening to the show? We ask that you support us as we continue to provide great content on the Geospatial industry discussing News, best practices, and having guest speakers related to the latest industry projects. You can contribute to our continued operation through https://anchor.fm/projectgeo/support and https://www.patreon.com/projectgeospatial Your contribution keeps our website running and funds our ability to cover conferences on various events beyond the GEOINT Symposium. If you represent a company in the industry and would like to talk about your product or service on our show please, reach out to us. Thanks for listening! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Spanning three years of featuring five unique datasets and challenges, SpaceNet® continues to apply various aspects of machine learning to solve difficult foundational mapping problems. Looking ahead, Payam Banazadeh, Founder & CEO of Capella Space, joins IQT CosmiQ’s Ryan Lewis and Jake Shermeyer to discuss the SpaceNet 6 Challenge which explores an under-explored modality of data: Synthetic Aperture Radar (SAR). The trio provide an overview on the importance of SAR data and its value in the upcoming challenge. SpaceNet is a collaboration between CosmiQ Works, Maxar Technologies, Amazon Web Services (AWS), Intel AI, Capella Space, Topcoder, and IEEE GRSS. Space Club Rule 42: When In Doubt, Use SAR.

We had the pleasure to interview Dan Brophy from Capella Space as he talks about who Capella is, what they are doing, and what is unique about the satellite constellation they are launching in March. Listen and check out what Dan has to say about this amazing new US-based satellite radar imaging company. About Capella Space Capella Space is an information services company that provides on-demand sub 0.5m very high-resolution Synthetic Aperture Radar (SAR) Earth observation imagery. Through a constellation of small satellites, Capella is providing easy access to frequent, timely and flexible information affecting dozens of industries worldwide. Capella’s high-resolution SAR satellites are matched with unparalleled infrastructure to deliver reliable global insights that sharpen our understanding of the changing world - improving decisions about commerce, conservation and well-being on Earth. Learn more at capellaspace.com. Support Project Geospatial Do you like hearing our podcast on Geospatial News, best practices, and guest speakers on industry best practices? You can contribute to our continued operation through: https://anchor.fm/projectgeo/support and https://www.patreon.com/projectgeospatial Your contribution keeps our website running and funds our participation to cover conferences on various events beyond the GEOINT Symposium. If you represent a company in the industry and would like to talk about your product or service on our show please reach out to us. Thanks for listening! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

This Week's Geospatial News for Week of 2019-12-18 In this segment Adam Simmons talks about the following: Capella Space - On December 16, 2019, Capella Space announced they will Start Commercial Operations in 2020 with Launch of Seven Synthetic Aperture Radar Satellites. Near Space Labs - It's a new company focused on providing persistent imagery monitoring from balloons over major metropolitan areas. NGA News - On December 17th, 2019 with a partnership with NOAA and the British Geological Society, NGA released the world magnetic model 2020 update. Batch Geocoder for Journalists - Erik Willems, a developer from Local Focus which creates data-driven web-tools for newsrooms, created a free batch geocoder. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Adam briefly goes over news related to Capella Space, Google Fusion Tables, and NGA's new campus West being built in St Louis. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

SpaceNet LLC is a non-profit organization dedicated to accelerating open source, artificial intelligence applied research for geospatial applications, specifically foundational mapping. Since its founding, the dataset has been downloaded millions of times in more than 80 countries. How did all of this get started? In the first of a two-part series, Ryan Lewis (CosmiQ Works), Todd Bacastow (Maxar), Joe Flasher (AWS), and Alexei Bastidas (Intel AI) discuss the origins of SpaceNet and how all the different partners contribute to this initiative.  SpaceNet is a collaboration between CosmiQ Works, Maxar, Intel AI, Amazon Web Services (AWS), and Capella Space.

It’s frustrating for environmental scientists to watch politicians mangle and regurgitate climate change data into stump campaign speeches. When Capella Space CEO Payam Banazadeh co-founded the San Francisco-based satellite constellation company in 2016, he set out on a mission to tell a clear, visual story about how our planet is changing, directly to the people who would be most impacted by those changes. Images are a universal language. In this episode, we caught up with Payam, a National Science Foundation fellow, NASA Mariner Award winner and entrepreneur recently named to Forbes “30 Under 30” list, about the unique capabilities of Synthetic Aperture Radar (SAR) data, specifically when used for environmental monitoring.  By using SAR data operating in the X-band, Capella’s constellation can see through clouds and in the dark, monitor stress points in physical infrastructure, extract critical soil and crop data for precision agriculture, prevent illegal fishing, and save lives. Once fully deployed, the Capella constellation will be able to monitor the entire planet, and provide a searchable data archive based on an in-house platform. We also spoke about Capella’s recent partnership with AddValue and Inmarsat and what new opportunities the constellation’s full deployment will bring to its global end-users.

When Capella Space's first prototype satellite launched in December 2018, it was the culmination of over three years of nonstop effort. Capella Space founder and CEO Payam Banazadeh explains how he fused experienced gained at the NASA Jet Propulsion Laboratory and Stanford's Management Science and Engineering masters program to build the satellite imaging company. As an early-stage CEO, he provides insights into the many risks and strategic decisions that precede product roll-out.

When Capella Space’s first prototype satellite launched in December 2018, it was the culmination of over three years of nonstop effort. Capella Space founder and CEO Payam Banazadeh explains how he fused experienced gained at the NASA Jet Propulsion Laboratory and Stanford’s Management Science and Engineering masters program to build the satellite imaging company. As an early-stage CEO, he provides insights into the many risks and strategic decisions that precede product roll-out.

When Capella Space’s first prototype satellite launched in December 2018, it was the culmination of over three years of nonstop effort. Capella Space founder and CEO Payam Banazadeh explains how he fused experienced gained at the NASA Jet Propulsion Laboratory and Stanford’s Management Science and Engineering masters program to build the satellite imaging company. As an early-stage CEO, he provides insights into the many risks and strategic decisions that precede product roll-out.

The first alert came on January 27. Two small satellites, whirling through Earth's low orbits, had “the potential for a conjunction.” Those are the words Major Cody Chiles, spokesperson for the Joint Force Space Component Command, uses to mean "the chance of a collision." The satellites, one from a company called Capella Space and the other from Spire Global, could smack into each other.

As Payam Banazadeh will tell you, Capella Space builds sophisticated satellites, but it's not a "satellite company." His company designs and launches rockets, but he insists it isn't strictly an "aerospace company" either. Instead, Capella's mission is more nuanced: To create a network of satellites capable of preventing disasters, boosting commerce, and saving lives.

This weeks podcast consists of three short interviews recorded at the Canadian Space Summit in Ottawa on November 28 and 29. Segment 1 (03:47) - In the first segment I spoke with Ryan Anderson, a co-founder of the Satellite Canada Innovation Network, known as SatCan. It was just over a year ago that I last spoke with Ryan in episode 22 about the new SatCan project. Since then, the organization tried unsuccessfully to be a part of the governments Supercluster program. However, the concept has is not dead and the founders diligently worked towards their goals and just prior to this weeks summit did announce that they had received some funding from the government. Ryan provides an update on what’s happening at SatCan. Segment 2 (18:42) - In the second segment I spoke with Professor Gordon Osinski from Western University’s Centre for Planetary Science and Exploration about a new national educational and public outreach initiative called Space Matters. Segment 3 (29:36) - In the last I ask SkyWatch co-founder and CEO James Slifierz on his initial thoughts of the news that Amazon had just announced a new service called Ground Station that could disrupt the current ground station model. Surprising many, the ground station offering, through Amazon’s Web Services, has Lockheed Martin as a partner. Currently available in preview mode for selected clients, the service has two ground stations managed by Lockheed Martin with an additional 10 to be added. Initial customers include Maxar’s DigitalGlobe, Spire, BlackSky, Capella Space, Open Cosmos and HawkEye 360. Ironically Jeff Bezos the founder of Amazon stands to benefit in a way many might not have thought of. Each year, according to Bezos, he sells some of his shares in Amazon to fund one of his other ventures, Blue Origin. It’s been reported he’s sold over a billion dollars of shares at various times. Now, thanks to this new AWS Ground Station offering, and in a roundabout way, those customers, using that service, will in part, it seems be helping Bezos fund the development of Blue Origin. Listen in.

A company that’s gearing up to send its first satellite to space, an AI-powered email startup acquired by Slack, and a meditation app that recently partnered with American Airlines to give passengers a calmer travel experience.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Payam Banazadeh, the co-founder and CEO of Capella Space (capellaspace.com), shines some light on the important topic of satellite surveillance. Banazadeh's company, Capella Space, is a venture-backed Silicon Valley company that builds satellites capable of imaging earth day and night, in all weather and light conditions. Banazadeh was named to the prestigious Forbes 30 Under 30 list in 2017 and Capella Space has been touted by The New York Times, Bloomberg, and Inc. as one of the top-25 disruptive companies in the world. Banazadeh graduated magna cum laude with a B.S. in aerospace engineering from The University of Texas at Austin.  During his time at UT, he received the Texas Outstanding Scholar & Leader Award for his formidable academic skills, performance, and exceptional leadership. Additionally, he holds a graduate business degree from Stanford University. Banazadeh received the NASA Mariner Award for his work on two multi-million dollar missions and the prestigious NASA Discovery Award for outstanding achievement in the formulation of novel concepts for the development of projects for NASA.  Banazadeh co-founded Capella Space with William Woods with the common goal of developing a means to monitor the planet more accurately and efficiently from space, which could have far-reaching applications for multiple industries. He discusses the frustration they shared as the world watched the unsuccessful search for Malaysian Airlines Flight 370 on live TV. Banazadeh and Woods collectively felt that there should be a better way to monitor the planet, and track objects such as airline flights, etc. He discusses some of their initial findings, reasons behind the ineffectiveness of satellites, such as satellites' inability to monitor in a comprehensive manner during cloudiness or darkness.  He describes how traditional satellites utilize optical imaging, which cannot see through either—clouds or darkness. Capella Space's satellites use Synthetic Aperture Radar (SAR) to achieve their excellent capabilities. SAR is a type of radar that can create 2D or 3D images of objects, such as landscapes, and it uses the motion of the radar antenna over a specific region to provide a sharper spatial resolution than traditional beam-scanning radars. Clouds and nighttime are no longer an issue, or a problem, with Capella Space's advanced technological satellites. Banazadeh gives a detailed explanation of the power and energy necessary to bounce satellite signals with the SAR system, and how Capella Space's satellites inhabit lower orbits to facilitate the power/energy and distance issues. He provides details on the measurements and imagery that exist with the SAR-based satellites versus traditional satellite technology that has been utilized in the past. He talks about the minute details that are visible with their company's offerings in the satellite technology arena, such as reflectivity, texture, and moisture information that is incredibly helpful for applications in many industries.  Banazadeh states that their strategy is not to observe the entire globe but to look at important, key areas globally where changes are occurring, changes that could severely impact security and industry. Capella Space's satellites can identify and classify most objects that are one meter or larger in size and can be accessed anywhere in the globe at any time, day or night. Additionally, they provide new imagery hourly and can easily penetrate clouds, fog, pollution, haze, and nearly every atmospheric condition. And with penetration and accuracy at such a high level, it's clear why Capella Space is attracting attention and praise for their outstanding leadership in global surveillance. 

In this episode we talk to Payam Banazadeh, the CEO and co-founder of Capella Space, a data company that provides persistent information from space through small satellites. 

The technology powering most satellites is remarkably limited. They're unable to image the surface of Earth in areas where it's cloudy or dark--which is about three-quarters of the planet at any given time. Payam Banazadeh, Founder and CEO of Capella Space discusses how this problem is being solved with tiny satellites that use synthetic aperture radar (SAR), a technology that can capture images in any light or weather condition. Payam provides his insights about how small satellites using SAR are opening the door to many new applications, from tracking soil moisture to assess the health of crops to more-accurate mapping for self-driving cars.

Shooting satellite photography is suboptimal at night. It's also hard to get a good picture through a cloud. But it's night on 50% of the globe at any given time. What's more, another 50% of earth is covered in clouds. (That means there are parts of the planet that are both dark and clouded.) All in all, only a certain percentage of satellite photos are actually usable. We're taking a lot of pictures of indistinguishable darkness. This is where Capella Space comes in, with tiny, backpack-sized satellites that can shoot at night and through clouds. “Because of that,” explains Payam Banazedeh, “We've got an unique opportunity to monitor important places around the world… completely regardless of what the weather and light conditions are.” Hit play to learn more about Capella Space and their new satellite technology. Subscribe, review, and if you can, donate some BitCoin to the cause. Every little bit helps.